{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:30:04Z","timestamp":1792726204731,"version":"4.5.0"},"reference-count":21,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2026,5,4]]},"DOI":"10.1080\/14740338.2026.2663185","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:55:44Z","timestamp":1776750944000},"page":"837-845","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["A novel, widespread impurity in mass-compounded tirzepatide\/B12 products: potential patient safety implications"],"prefix":"10.1080","volume":"25","author":[{"given":"Brad","family":"Jordan","sequence":"first","affiliation":[{"name":"Global Regulatory Affairs Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Arbogast","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Clemens","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Huang","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Snyder","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280261421979"},{"key":"e_1_3_6_4_1","unstructured":"U.S. Food and Drug Administration. FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s. Silver Spring (MD): FDA; [cited 2026 Apr 2]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s"},{"key":"e_1_3_6_5_1","unstructured":"\u2022U.S. Food and Drug Administration. Compounding and the FDA: questions and answers. Silver Spring (MD): FDA; [cited 2026 Mar 23]. Available from: https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/compounding-and-fda-questions-and-answers"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-020-00814"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2022.03.010"},{"key":"e_1_3_6_8_1","unstructured":"U.S. Food and Drug Administration. FDA adverse event reporting system (FAERS) public dashboard [Internet]. Silver Spring (MD): FDA; [cited 2026 Feb 1]. Available from: https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2025.2499670"},{"key":"e_1_3_6_10_1","unstructured":"\u2022U.S. Food and Drug Administration. FDA\u2019s concerns with unapproved GLP-1 drugs used for weight loss [Internet]. Silver Spring (MD): FDA; [cited 2026 Jan 12]. Available from: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"},{"key":"e_1_3_6_11_1","unstructured":"Code of Federal Regulations. Title 21 \u00a7300.50(a)."},{"key":"e_1_3_6_12_1","unstructured":"U.S. Food and Drug Administration. Guidance for industry: Q3A impurities in new drug substances. Silver Spring (MD): FDA; 2008 Jun."},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.8b04283"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinorgbio.2023.112154"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.36347\/sajp.2022.v11i10.001"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature02261"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1039\/d1cb00067e"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13222"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14089"},{"key":"e_1_3_6_20_1","unstructured":"IQVIA. The compounded GLP-1 market. 2025 Oct 22. Available from: https:\/\/tinyurl.com\/mpze2srt"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.0453"},{"key":"e_1_3_6_22_1","unstructured":"U.S. Food and Drug Administration. FDA recall dashboard [Internet]. Silver Spring (MD): FDA; [cited 2026 Jan 23]. Available from: https:\/\/datadashboard.fda.gov\/oii\/cd\/recalls.htm"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.5018"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2026.2663185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:19:20Z","timestamp":1777882760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2026.2663185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,4]]}},"alternative-id":["10.1080\/14740338.2026.2663185"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2026.2663185","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-03-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}